AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Lyra Therapeutics 15min Chart MACD Death Cross & Bearish Marubozu Detected
ByAinvest
Friday, Aug 15, 2025 1:48 pm ET1min read
Lyra Therapeutics' 15-minute chart has exhibited a MACD Death Cross and a Bearish Marubozu pattern as of August 15, 2025 at 13:45. This indicates that the stock price is likely to continue declining, with sellers dominating the market and bearish momentum expected to persist.
Lyra Therapeutics Inc. (LYRA) has seen a significant shift in market sentiment following the appearance of a MACD Death Cross and a Bearish Marubozu pattern on its 15-minute chart as of August 15, 2025, at 13:45. This technical indicator suggests a potential decrease in the stock price, with sellers currently in control of the market and bearish momentum expected to persist [1].The MACD Death Cross and Bearish Marubozu patterns indicate that the stock price is moving towards the downside, signaling a potential decrease in value. Traders and investors should be cautious, as the momentum is shifting in favor of sellers. The current market conditions suggest that the stock may face further declines, highlighting the need for investors to closely monitor the situation.
Lyra Therapeutics is set to report its quarterly earnings on August 12, 2025. Analysts expect a significant fall in revenue and a loss per share. The mean analyst estimate for Lyra Therapeutics Inc. is for a loss of $6.02 per share, unchanged from the previous three months. The current average analyst rating on the shares is "hold," with no "strong buy" or "buy" recommendations, four "hold" recommendations, and no "sell" or "strong sell" recommendations. The Wall Street's median 12-month price target for Lyra Therapeutics Inc. is $23.00, about 70% above its last closing price of $6.89 [1].
Previous quarterly performance indicates a trend of missed earnings estimates and a decline in revenue. For instance, in the quarter ending June 30, 2024, Lyra Therapeutics reported a loss of $16.42 per share, missing the analysts' estimate of $16.40 per share by 125.6% [1].
Lyra Therapeutics' recent financial performance and market conditions suggest that the company may face challenges in the coming quarters. Investors should closely monitor the company's earnings report and market conditions to make informed decisions.
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U024H:0-lyra-therapeutics-inc-expected-to-post-a-loss-of-6-02-a-share-earnings-preview/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet